First-Line and Neoadjuvant Immunotherapy for Gastric Cancer

Recruiting now

Conditions studied: Advanced Gastric Cancer, Locally Advanced Gastric Carcinoma

In brief

This prospective observational study aims to evaluate the efficacy and safety of immune checkpoint inhibitors as first-line and neoadjuvant therapy for advanced gastric cancer, while also investigating relevant biomarkers to better understand their role in immunotherapy outcomes

Key facts

Study ID
NCT06727981
Run by
Qilu Hospital of Shandong University
People needed
500
Starts
2022-01-15
Expected to finish
2028-01-15
Last updated by the study team
2024-12-11

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.